Therapy

American Journal of Gastroenterology Publishes Data from HighTide Therapeutics' Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis

Retrieved on: 
Wednesday, November 16, 2022
AST, ALP, Type 2 diabetes, Malignancy, Serum, Liver transplantation, HighTide, PSC, Risk, Liver disease, GGT, Therapy, Hypertriglyceridemia, Primary sclerosing cholangitis, Patient, IBD, Liver failure, Orphan drug, Fast Track, NASH, Inflammation, Disease, T2DM, News, Cirrhosis, ALT, Ulcerative colitis, Fibrosis, The American Journal of Gastroenterology, Inflammatory bowel disease, Crohn's disease, American Journal, Safety, Fatty liver disease, Pharmaceutical industry, Medical imaging, MD

This study met the primary endpoint and multiple key secondary endpoints, demonstrating the safety and efficacy of HTD1801 in treating PSC.

Key Points: 
  • This study met the primary endpoint and multiple key secondary endpoints, demonstrating the safety and efficacy of HTD1801 in treating PSC.
  • Data show that compared to placebo, both low and high doses of HTD1801 treatment could significantly reduce serum ALP levels.
  • In addition, HTD1801 significantly reduced alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT), further supporting the beneficial effects of HTD1801 in treating PSC.
  • The improvements in ALP we observed in this study, along with the excellent safety profile of HTD1801, are promising.

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares

Retrieved on: 
Sunday, November 27, 2022
Inflammation, Euroclear, Financial Services and Markets Act 2000, Therapy, European Economic Area, Protein, Drug development, Security (finance), Communication, AFRICA, Kohlberg Kravis Roberts, Qualifying investor alternative investment fund, Patient, Financial services, Prospectus, Risk, Fibrosis, Person, Relevance (Person of Interest), Issuer, KKR, European Union (Withdrawal) Act 2018, Disease, EUR, AMERICA, Urban economics, Council, Sale, Cancer, Article, European Parliament, Euronext Amsterdam, Investment, Pharmaceutical industry, EU

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.

Key Points: 
  • NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.
  • Vivoryon is pioneering a unique therapeutic approach to overcoming the challenges in Alzheimers disease ("AD") drug development.
  • Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines.
  • Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases.

Pharnext: completion of the reverse split of its shares on the basis of 1 new share for 5,000 old shares, start of trading of the shares resulting from the reverse split, and capital reductions

Retrieved on: 
Sunday, November 27, 2022
Risk, Therapy, Parity, ISIN, Charcot–Marie–Tooth disease, Neurodegeneration, Treasury, Exercise, Security (finance)

These adjustments are applicable from the date of allocation of the new shares resulting from the reverse stock split, i.e.

Key Points: 
  • These adjustments are applicable from the date of allocation of the new shares resulting from the reverse stock split, i.e.
  • The Company also carried out two capital reductions motivated by losses.
  • As a result of this capital reduction, the share capital is reduced from 3,932,043 euros to 39,320.43 euros and is divided into an unchanged number of shares, i.e.
  • Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases that currently lack curative and/or disease-modifying treatments.

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022

Retrieved on: 
Sunday, November 27, 2022
Report, Inflammation, Therapy, Patient, Protein, Cancer, Risk, Fibrosis, Euronext Amsterdam, Pharmaceutical industry

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022

Key Points: 
  • Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022
    The issuer is solely responsible for the content of this announcement.
  • The report will be available for download on the Company's website ( https://www.vivoryon.com/investors-news/financial-information/ ).
  • Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements and from expectations.
  • Certain risk factors that may affect the Companys future financial results are discussed in the published annual financial statements of the Company.

EQS-News: Defence Therapeutics Inc.: DEFENCE’S SUCCESSFULL STUDY ON THE ACCUVAC-PT007 VACCINE TARGETING CERVICAL CANCER

Retrieved on: 
Sunday, November 27, 2022
Cervical cancer, Human papillomavirus infection, Oropharyngeal cancer, ADC, Tongue, Diagnosis, Pharma, Immune system, Catastrophic illness, Control, Infection, Engineering, Cell, Cancer, Good laboratory practice, Therapy, Partnership, Patient, Mortality, USD, GLP, Vulva, Antigen presentation, Neoplasm, Vaccination, Epithelium, E7, HPV, L1, Wart, CSE, News, Vaccine, Safety, Vagina, Penis, Security (finance), Pharmaceutical industry, Birth control, Defense

Cervical cancer normally occurs when epithelial cells of the cervix are infected with the human papillomavirus (HPV), one of the most common sexually transmitted disease.

Key Points: 
  • Cervical cancer normally occurs when epithelial cells of the cervix are infected with the human papillomavirus (HPV), one of the most common sexually transmitted disease.
  • Currently, vaccination targeting HPV directly can protect from cervical cancer.
  • This vaccine can not only be used to protect from HPV (prophylactic use), but it is the only experimental vaccine capable of curing established cervical cancer when combined to immune-checkpoint inhibitors.
  • Using the AccumTM platform, Defence developed the AccuVAC-PT007, a protein-based vaccine targeting the E7 oncoprotein of the HPV virus.

Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China

Retrieved on: 
Sunday, November 27, 2022
MAPK, Humanitarian use licenses, National Institute of Virology, COVID-19, Probability, Pioglitazone, Knowledge, API, Patient, Mortality, Ageing, Disease, Drug development, Patent, HIV disease progression rates, AMD, Research, Therapy, Fibrosis, IPF, Severe acute respiratory syndrome coronavirus 2, Trial of the century, MAP, Idiopathic pulmonary fibrosis, KNRS, Pharmaceutical industry, Virology, Muthiri kinaru

Kinarus Therapeutics Holding AG (SIX: KNRS) (Kinarus), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announced today that it has engaged Great Health Companion Group Ltd (GHCG), a subsidiary of Hakim Unique Group, a global conglomerate from China, to explore partnering options to initiate Phase 2 testing of KIN001 to treat wet age-related macular degeneration (wAMD) and idiopathic pulmonary fibrosis (IPF).

Key Points: 
  • Kinarus Therapeutics Holding AG (SIX: KNRS) (Kinarus), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announced today that it has engaged Great Health Companion Group Ltd (GHCG), a subsidiary of Hakim Unique Group, a global conglomerate from China, to explore partnering options to initiate Phase 2 testing of KIN001 to treat wet age-related macular degeneration (wAMD) and idiopathic pulmonary fibrosis (IPF).
  • In addition, Kinarus and GHCG will explore further business opportunities which may include licensing or strategic partnerships.
  • Dr Alexander Bausch, CEO of Kinarus Therapeutics Holding AG, commented: China has the worlds largest population and second largest economy.
  • Kinarus Therapeutics Holding AG (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland.

EQS-News: HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor

Retrieved on: 
Sunday, November 27, 2022
Doctor of Philosophy, German Cancer Aid, MKK4, 2021 Essex County Council election, University, Therapy, Bayer, Sanofi, Patient, Senior advisor, Liver regeneration, Max Planck Institute for Molecular Genetics, Max, German Cancer Research Center, Transplant, Innovation, Max Planck Society, Pharmacy, Shire, Research, Publication, Hoechst, Survival, Takeda, Drug discovery, Pharmaceutical industry, Pharmacology

Tbingen (Germany), November 23, 2022 HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the appointment of Dr. Andreas Busch as Senior Advisor.

Key Points: 
  • Tbingen (Germany), November 23, 2022 HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the appointment of Dr. Andreas Busch as Senior Advisor.
  • We are thrilled to welcome Andreas Busch to our team.
  • Dr. Andreas Busch added: There is an enormous lack of organs for transplantation including of livers despite their unique inherent regenerative capabilities.
  • Dr. Andreas Busch has an extensive track record in facilitating innovation both in the pharmaceutical industry as well as in academic research.

Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001

Retrieved on: 
Sunday, November 27, 2022
MAPK, Humanitarian use licenses, COVID-19, Inflammation, ARIPO, Retina, United States patent law, Probability, United States Patent and Trademark Office, Pioglitazone, Knowledge, IgG4-related ophthalmic disease, API, Ageing, Drug development, AMD, Therapy, Patent, IPF, EP, Trial of the century, Idiopathic pulmonary fibrosis, KNRS, Pharmaceutical industry, Muthiri kinaru

16/500,504 Methods of preventing or treating Ophthalmic Diseases covering its therapeutic candidate KIN001 in age-related macular degeneration (AMD).

Key Points: 
  • 16/500,504 Methods of preventing or treating Ophthalmic Diseases covering its therapeutic candidate KIN001 in age-related macular degeneration (AMD).
  • 11285155 that protects the KIN001 pharmaceutical combination of pamapimod and pioglitazone until at least 2037.
  • Kinarus is currently developing KIN001 as an oral treatment for wet age-related macular degeneration, idiopathic pulmonary fibrosis, and Covid-19.
  • Kinarus possesses the exclusive worldwide license to pamapimod from Roche Pharmaceuticals Ltd. covering all therapeutic indications.

EQS-News: Women’s Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash Flow

Retrieved on: 
Sunday, November 27, 2022
Body mass index, Growth, Skin, CHC, Planned Parenthood, Female, Advertising, Partnership, Therapy, Patient, Ethinylestradiol, Birth, BMI, Health, LNG, Levonorgestrel, Agile, GAAP, Freedom, Woman, HOLX, Hologic, Birth control, Video game, Bank, Contraceptive patch, Corium

On Nov. 7, Agile released financial results for the three months that ended Sept. 30 and provided a corporate update.

Key Points: 
  • On Nov. 7, Agile released financial results for the three months that ended Sept. 30 and provided a corporate update.
  • This was an increase of 43% from the second quarter of 2022 the largest quarter-over-quarter increase the Company has achieved.
  • The decrease reflects the elimination of an inventory obsolescence reserve, which the company established in the third quarter of 2021.
  • Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of todays women.

APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival

Retrieved on: 
Sunday, November 27, 2022
Phenylketonuria, Hypochlorous acid, Food, SIX Swiss Exchange, Life, Therapy, Metabolism, Patient, Urea, Pulmonology, Epidermolysis bullosa, PKU, Acer, Diet, Disease, Orphan, Patent, Child, Maple syrup urine disease, Pathology, Connective tissue, Absorption, OTCQB, RLF, Organic acid, APR, Entertainment, Pharmaceutical industry

Geneva, Switzerland, November 21, 2022 RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) (Relief), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, today announced that its wholly owned subsidiary APR Applied Pharma Research SA (APR) has been nominated as a finalist in the 2022 Rare Disease International Film Festival UnoSguardoRaro .

Key Points: 
  • Geneva, Switzerland, November 21, 2022 RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) (Relief), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, today announced that its wholly owned subsidiary APR Applied Pharma Research SA (APR) has been nominated as a finalist in the 2022 Rare Disease International Film Festival UnoSguardoRaro .
  • APR supports and contributes to the first and only European film festival showcasing films from around the world that address the challenges of life with a rare disease.
  • As part of its participation in the festival, APR attended events in Berlin (Il Kino), Rome (la Casa del Cinema) and Milan (Niguarda hospital).
  • The festival earned the support of many rare disease associations such as:
    PKU GOLIKE is a phenylalanine-free food intended for the dietary management of phenylketonuria (PKU).